NeuroD1 Expression in Human Prostate Cancer: Can It Contribute to Neuroendocrine Differentiation Comprehension?

European Urology

Volumn 52, Issue 5, 2007, Pages 1365-1373

  Cindolo, Luca ^a   Franco, Renato ^b   Cantile, Monica ^c   Schiavo, Giulia ^c   Liguori, Giuseppina ^b   Chiodini, Paolo ^d   Salzano, Liugi ^a   Autorino, Riccardo ^d   Di Blasi, Arturo ^a   Falsaperla, Mario ^e   Feudale, Elisa ^f   Botti, Gerardo ^b   Gallo, Antonio ^b   Cillo, Clemente ^c  

^a G RUMMO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

CD56; Chromogranin A; NeuroD1; Neuroendocrine differentiation; Prostate cancer; Synaptophysin

Indexed keywords

CD56 ANTIGEN; CHROMOGRANIN A; CYCLIC AMP; NEUROGENIC DIFFERENTIATION FACTOR; SYNAPTOPHYSIN;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AGED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMOGRANIN A; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HELIX-LOOP-HELIX MOTIFS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 34648844152     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.11.030     Document Type: Article

References (27)

1. Di Sant'Agnese P.A. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 70 (1992) 254-268
2. Di Sant'Agnese P.A. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 23 (1992) 287-296
3. Vashchenko N., and Abrahamsson P.-A. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47 (2005) 147-155
4. Mosca A., Dogliotti L., Berruti A., et al. Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: prostate cancer. Dig Liver Dis 36 Suppl 1 (2004) 60-67
5. Berruti A., Dogliotti L., Mosca A., et al. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. Prostate 47 (2001) 205-211
6. Shariff A.H., and Ather M.H. Neuroendocrine differentiation in prostate cancer. Urology 68 (2006) 2-8
7. Cantile M., Kisslinger A., Cindolo L., et al. cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved in vivo with neuroendocrine differentiation of human advanced prostate cancers. J Cell Physiol 205 (2005) 202-210
8. Petrovics G., Zhang W., Makarem M., et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 23 (2004) 605-611
9. Lee J.E., Hollenberg S.M., Snider L., et al. Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. Science 268 (1995) 836-884
10. Liu M., Pleasure S.J., Collins A.E., et al. Loss of BETA2/NeuroD leads to malformation of the dentate gyrus and epilepsy. Proc Nat Acad Sci USA 97 (2000) 865-870
11. Chae J.H., Stein G.H., and Lee J.E. NeuroD: The predicted and the surprising. Mol Cells 18 (2004) 271-288
12. Schonhoff S.E., Giel-Moloney M., and Leiter A.B. Development and differentiation of gut endocrine cells. Endocrinology 145 (2004) 2639-2644
13. Fujii A., Kamiakito T., Takayashiki N., et al. Neuroendocrine tissue-specific transcription factor, BETA2/NeuroD, in gastric carcinomas: a comparison with chromogranin-A and synaptophysin expressions. Pathol Res Pract 199 (2003) 513-519
14. Naya F.J., Huang H.P., Qiu Y., et al. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neurod-deficient mice. Genes Dev 11 (1997) 2323-2334
15. Suhardja A., Kovacs K., and Rutka J. Genetic basis of pituitary adenoma invasiveness: a review. J Neurooncol 52 (2001) 195-204
16. Hu Y., Ippolito J.E., Garabedian E.M., et al. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 277 (2002) 44462-44474
17. Sinisi A.A., Chieffi P., Pasquali D., et al. EPN: a novel epithelial cell line derived from human prostate tissue. In Vitro Cell Dev Biol Anim 38 (2002) 165-172
18. Theodorescu D., Broder S.R., Boyd J.C., et al. Cathepsin D and chromogranin-A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80 (1997) 2109-2119
19. Bostwick D.G., Qian J., Pacelli A., et al. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 168 (2002) 1204-1211
20. Slovin S.F. Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?. Nat Clin Pract Urol 3 (2006) 138-144
21. Sasaki T., Komiya A., Suzuki H., et al. Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 48 (2005) 224-229
22. Singh D., Febbo P.G., Ross K., et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1 (2002) 203-209
23. Laczkó I., Hudson D.L., Freeman A., et al. Comparison of the zones of the human prostate with the seminal vesicle: morphology, immunohistochemistry, and cell kinetics. Prostate 62 (2005) 260-266
24. Cox M.E., Deeble P.D., Lakhani S., et al. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 59 (1999) 3821-3830
25. Wright M., Tsai M., and Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17 (2003) 1726-1737
26. Chen T., Cho R.W., Stork P.J.P., et al. Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 59 (1999) 213-218
27. Zelivianski S., Verni M., Moore C., et al. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochimica Biophysica Acta 1539 (2001) 28-43